Trial
NCT05245071
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Non-squamous Non-small Cell Lung Cancer
Intervention
Tusamitamab ravtansine
Why stopped
Sponsor decision, the decision is not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-29